BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• Drug Development

  Medivation, Inc. Release: The New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial Of Enzalutamide In Men With Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy

  June 2, 2014

   · 

  7 min read
• Business

  Seres Health Appoints Former Merck & Co., Inc. Senior Executive, Roger J. Pomerantz, M.D., F.A.C.P., As Chief Executive Officer And Chairman

  June 2, 2014

   · 

  3 min read
• Genetown

  ArQule, Inc. Announces Data Presentations With Tivantinib To Be Featured At American Society of Clinical Oncology 2014

  June 2, 2014

   · 

  1 min read
• Business

  FORMA Therapeutics, Inc. Appoints Duncan Walker, Ph.D., To R&D Leadership Team

  June 2, 2014

   · 

  1 min read
• BioMidwest

  MagForce AG To Present At Dbaccess German, Swiss & Austrian Conference 2014, Held By Deutsche Bank From June 11-13 In Berlin

  June 2, 2014

   · 

  1 min read
• Cancer Breakthrough Team At Morphogenesis, Inc. Announces New Worldwide Cancer Vaccine Update

  June 2, 2014

   · 

  2 min read
• Drug Development

  Ariad Pharmaceuticals, Inc. Announces Longer-Term Safety And Efficacy Data Of Ponatinib From PACE And Phase 1 Clinical Trials

  June 2, 2014

   · 

  1 min read
• Job Trends

  Arrow International, Inc. To Significantly Downsize, Will Cost 600 North Carolina Jobs

  June 2, 2014

   · 

  1 min read
• Policy

  Organogenesis Inc. Sales Rep Charged With Stealing $350K Worth Of Skin Grafts

  June 2, 2014

   · 

  1 min read
• Drug Development

  Bristol-Myers Squibb Company Release: One- & Two-Year Survival Rates of 94% And 88% Announced From Phase 1b Trial Of Investigational PD-1 Checkpoint Inhibitor Nivolumab And Yervoy® (ipilimumab) In Advanced Melanoma; Ongoing Phase 2/3 Trials To Confirm Res

  June 2, 2014

   · 

  1 min read